Compare Bank of America Corp (BAC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Summit Therapeutics Inc — how do they compare? Bank of America Corp trades at $64.73 (market cap $447.54B), while Summit Therapeutics Inc trades at $15.28 (market cap $12.06B). The key difference: Bank of America Corp is far larger — about 37.1× Summit Therapeutics Inc's market cap, and Bank of America Corp pays a 2% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BAC | SMMT | |
|---|---|---|
Market Cap | $447.54B | $12.06B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $26.98 |
52-Week Low | $46.72 | $12.55 |
Dividend Yield | 2% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $63.86, up 1.09% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and revenue growth to $113.10B in 2025. Analyst consensus is strongly positive, with a $67.36 price target and 35 buy ratings. Recent news highlights strategic partnerships and hiring initiatives, reinforcing growth prospects.
BAC presents a favorable investment opportunity driven by earnings beats, robust deposit franchise, and potential capital returns post-stress tests. Risks include interest rate sensitivity and macroeconomic volatility. The stock's current valuation at a P/E of 14.78 offers room for upside relative to historical averages, supported by institutional bullishness.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
